IL150222A0 - Pharmaceutical compositions containing a gepirone metabolite - Google Patents

Pharmaceutical compositions containing a gepirone metabolite

Info

Publication number
IL150222A0
IL150222A0 IL15022200A IL15022200A IL150222A0 IL 150222 A0 IL150222 A0 IL 150222A0 IL 15022200 A IL15022200 A IL 15022200A IL 15022200 A IL15022200 A IL 15022200A IL 150222 A0 IL150222 A0 IL 150222A0
Authority
IL
Israel
Prior art keywords
gepirone
pharmaceutical compositions
compositions containing
gepirone metabolite
metabolite
Prior art date
Application number
IL15022200A
Other languages
English (en)
Inventor
Edward H Ruediger
Joseph P Yevich
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Publication of IL150222A0 publication Critical patent/IL150222A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15022200A 1999-12-20 2000-12-18 Pharmaceutical compositions containing a gepirone metabolite IL150222A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (1)

Publication Number Publication Date
IL150222A0 true IL150222A0 (en) 2002-12-01

Family

ID=26868346

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15022200A IL150222A0 (en) 1999-12-20 2000-12-18 Pharmaceutical compositions containing a gepirone metabolite
IL150222A IL150222A (en) 1999-12-20 2002-06-13 Pharmaceutical preparations containing Gifiron metabolism

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150222A IL150222A (en) 1999-12-20 2002-06-13 Pharmaceutical preparations containing Gifiron metabolism

Country Status (20)

Country Link
US (1) US6534507B1 (pl)
EP (1) EP1242061B1 (pl)
JP (1) JP4236407B2 (pl)
KR (1) KR100602976B1 (pl)
CN (1) CN1411375A (pl)
AT (1) ATE294572T1 (pl)
AU (1) AU776409B2 (pl)
CA (1) CA2395458C (pl)
CZ (1) CZ300429B6 (pl)
DE (1) DE60019968T2 (pl)
ES (1) ES2241683T3 (pl)
HU (1) HU228963B1 (pl)
IL (2) IL150222A0 (pl)
MX (1) MXPA02006146A (pl)
NO (1) NO323304B1 (pl)
NZ (1) NZ519554A (pl)
PL (1) PL200378B1 (pl)
PT (1) PT1242061E (pl)
RU (1) RU2282448C2 (pl)
WO (1) WO2001045687A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016347A1 (en) * 2000-08-22 2002-02-28 Akzo Nobel N.V. Active metabolite of gepirone
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
US6897309B2 (en) 2002-08-12 2005-05-24 Bristol-Myers Squibb Company Process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050165233A1 (en) * 2003-11-18 2005-07-28 Mourad Hamedi Continuous process for producing hydroxyazapirones by oxidation
EP1809255A4 (en) * 2004-11-05 2011-08-03 Fabre Kramer Holdings Inc HIGH DOSAGE FORMULATION OF GEPIRON WITH EXTENDED RELEASE
WO2009137679A1 (en) * 2008-05-08 2009-11-12 Fabre Kramer Pharmaceuticals, Inc. 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
DE69032725T2 (de) * 1989-05-31 1999-04-08 Pharmacia & Upjohn Co., Kalamazoo, Mich. ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
EP1242061A2 (en) 2002-09-25
MXPA02006146A (es) 2004-08-23
CA2395458A1 (en) 2001-06-28
AU776409B2 (en) 2004-09-09
HU228963B1 (en) 2013-07-29
DE60019968T2 (de) 2006-02-02
KR20020082470A (ko) 2002-10-31
NZ519554A (en) 2005-01-28
DE60019968D1 (de) 2005-06-09
CZ300429B6 (cs) 2009-05-20
ATE294572T1 (de) 2005-05-15
CA2395458C (en) 2009-05-12
ES2241683T3 (es) 2005-11-01
RU2002119400A (ru) 2004-01-27
JP4236407B2 (ja) 2009-03-11
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
EP1242061B1 (en) 2005-05-04
WO2001045687A2 (en) 2001-06-28
NO20022954D0 (no) 2002-06-19
KR100602976B1 (ko) 2006-07-20
RU2282448C2 (ru) 2006-08-27
HUP0301831A2 (hu) 2003-09-29
AU2268701A (en) 2001-07-03
NO323304B1 (no) 2007-03-05
CZ20022137A3 (cs) 2003-03-12
JP2004500362A (ja) 2004-01-08
US6534507B1 (en) 2003-03-18
PL364936A1 (pl) 2004-12-27
WO2001045687A3 (en) 2002-04-25
IL150222A (en) 2009-09-22
NO20022954L (no) 2002-06-19
CN1411375A (zh) 2003-04-16

Similar Documents

Publication Publication Date Title
US5698558A (en) Methods for treating allergic disorders using optically pure (-) cetirizine
AU2002360462A8 (en) Compositions containing both sedative and non-sedative antihistamines
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
US6319927B1 (en) Method of using levocetirizine and pharmaceutical compositions containing the same for inducing sleep
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
IL150222A0 (en) Pharmaceutical compositions containing a gepirone metabolite
MY129450A (en) Pharmaceutical composition
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
CA2005987A1 (en) Therapeutically active substituted benzimidazole and process for its preparation
RU2005122403A (ru) Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов
EP0661975A1 (en) Methods and compositions for treating allergic disorders using optically pure (+) cetirizine
PE20011004A1 (es) Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4
RU2002118304A (ru) Способ подавления чувства страха
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
ES2089974A1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
JP2004517808A5 (pl)
SE9902935D0 (sv) Pharmaceutical compositions
MY143571A (en) Eplerenone crystalline form
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
DE3867042D1 (de) Pharmazeutische praeparate.
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
SE9904412D0 (sv) Comminuted form